BiomX Issues Statement Regarding Recent Common Stock Trading Activity

Rhea-AI Summary

BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock. The company said it is not aware of any undisclosed material developments in its business or affairs that would explain the activity.

BiomX noted that NYSE American contacted the company per usual practice and requested this statement. The company indicated it does not intend to provide further comment about market speculation or trading activity.

News Market Reaction – PHGE

+69.51% 51.3x vol

25 alerts

+69.51% Session close to close

+12.7% Peak Tracked

-42.4% Trough Tracked

$10.61M Market Cap

51.3x Rel. Volume

In the Jan 27 session, PHGE gained 69.51%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.7% during that session. Argus tracked a trough of -42.4% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 51.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +69.5% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +69.5% in the session following this news. A strong positive reaction aligns with the stock’s history of moving in step with news tone, even when events are financial or structural. Recent catalysts included a 1-for-19 reverse split and a $3.0M private placement, plus earlier volatility around BX004. However, this statement explicitly cites no new undisclosed developments, so any large upside would have reflected trading dynamics and sector strength rather than fresh company fundamentals.

Historical Context

5 past events · Latest: Dec 29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 29	Private placement	Neutral	+3.6%	Announced $3.0M private placement to support BX011 and strategic review.
Dec 08	Trial discontinuation	Negative	-36.9%	Ended BX004 Phase 2b after high adverse events and began cost cuts.
Nov 25	Clinical update	Neutral	+5.4%	Provided BX004 Phase 2b safety update and pushed topline results to Q2 2026.
Nov 14	Reverse stock split	Neutral	+7.5%	Announced 1-for-19 reverse stock split and share count reduction.
Nov 12	Earnings and update	Negative	-1.9%	Reported Q3 2025 results with limited cash and going concern language.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Price reactions have generally aligned with news tone, including a sharp selloff on negative BX004 discontinuation news and positive responses to financing and corporate actions.

Recent Company History

Over the last few months, BiomX has navigated clinical, financial, and capital structure shifts. Negative news such as discontinuation of the BX004 Phase 2b trial and insolvency proceedings for an Israeli subsidiary coincided with a -36.94% drop. Corporate actions, including a 1-for-19 reverse split and a $3.0M private placement, saw modest positive reactions. Earnings and liquidity updates highlighted limited cash into Q1 2026. Today’s statement simply notes no undisclosed material developments behind unusual trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock.

The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock.

NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement. The Company does not intend to make any further comment on market speculation or trading activity.

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Contacts:

BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com

FAQ

What did BiomX (PHGE) say about the January 27, 2026 unusual trading?

BiomX said it is not aware of any undisclosed material developments that would explain the recent unusual trading activity.

Did BiomX (PHGE) confirm any new business developments on January 27, 2026?

No. BiomX stated it is not aware of any material developments in its business or affairs that have not been previously disclosed.

Why did BiomX (PHGE) issue the trading statement on January 27, 2026?

The company said NYSE American contacted it in accordance with usual practice and advised that it issue a statement.

Will BiomX (PHGE) provide more details about the market activity after January 27, 2026?

BiomX stated it does not intend to make any further comment on market speculation or trading activity.

Does the January 27, 2026 statement from BiomX (PHGE) include financial or clinical updates?

No. The statement only addressed trading activity and said there were no undisclosed material developments; it did not provide financial or clinical updates.